BioNTech (BNTX) maintains a &#34;Strong Buy&#34; rating due to positive phase 3 data for gotistobart in second-line squamous NSCLC patients, showing a substantial reduction in the risk of death compared to docetaxel. Upcoming pivotal phase 3 data in 2026 and pipeline expansion into other cancers represent significant future catalysts. The company's robust cash position, strengthened by a $1.5B upfront payment from Bristol-Myers Squibb, further supports its extensive clinical development and strategic acquisitions.

BNTX

<p>BioNTech (BNTX) 維持 “強烈買入” 評級，原因是其在二線鱗狀非小細胞肺癌患者中獲得了積極的三期數據，顯示與多西他賽相比，死亡風險顯著降低。即將在 2026 年發佈的關鍵三期數據以及向其他癌症領域的管線擴展代表了未來的重要催化劑。該公司強勁的現金狀況得益於來自百時美施貴寶的 15 億美元預付款，進一步支持其廣泛的臨牀開發和戰略收購</p>

BioNTech：在下一代抗 CTLA-4 藥物 Gotistobart 第一階段成功後，維持 “強烈買入” 評級